Next Phase Newsletter

A strategic consulting firm has a venture capital arm with offices in the US Midwest and Shanghai, China. Alongside investments, the firm advises life science companies on strategic partnerships (manufacturers, distributors) in the China market by providing resources in the network. The firm is currently raising a fund predicted to close mid-year 2016. The firm is seeking five new investments within the next year, and typically makes $1M to several million dollar investments per company in Series A, B, and C rounds. The firm focuses on US-based companies, though is open to companies on a global-level.

The firm is indication agnostic and open to technology in all sectors of life science – medical devices, therapeutics, diagnostics, and healthcare IT. In terms of phase of development, the firm requires the company to at least have a prototype, and for therapeutics to be in clinical trials, preferably in Series B. The firm will also look at on-the-market products as well as lab equipment and drug development enabling technology.

The firm requires the company to be in Series A, B, or C. The firm prefers the company to have or seek to have their technology in the China market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital and private equity firm with offices in Israel and Massachusetts has historically invested in in very early stage companies in therapeutics and diagnostics, but now is moving to mid-stage to later stage companies, primarily in medical devices. While the firm has made several lead investments, the firm typically co-invests, seeking partners with large USA private equity funds to make co-investments at $20 million and upwards. The firm currently manages a $120 million fund, and looks to make 2-3 investments within the next year. The firm is open to companies based in the USA, Europe, Israel, and Canada.

While having made investments in therapeutics and diagnostics in the past, the firm now focuses on innovative medical devices. The firm is open to 510K and PMA devices, as well as all indications. The firm prefers to see later stage post-product technology with proven clinical data, and may be interested in companies in clinical stages close to commercialization. The firm is also open to lab equipment and drug development enabling technology.

The firm requires companies to have an established management team, though will also help fill the team, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office based on the US East Coast has a venture fund that makes direct venture investments in healthcare and technology startups. The fund was established by successful entrepreneurs and investors to meet the need for seed and early stage funding for life science and healthcare companies. The fund has an evergreen structure and can allocate up to $3M (in equity or loans) per company. The fund seeks to invest in companies based in the US. The fund is actively seeking new investments and looks to make about 2 allocations in the next 6-9 months.

In the life sciences, the fund is currently seeking to invest in early stage medical devices. The fund is opportunistic in terms of subsectors and indications, but generally does not invest in devices that require a PMA, or which will require over $50 million in total development costs. The fund is particularly interested in dental devices, cosmetics, and mobile technology.

The firm requires a board seat in each portfolio company. The firm seeks a company with a strong management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A US-based venture capital firm founded in 2015 is investing from its first fund. The firm invests in early-stage technology companies, and prefers to invest in companies from concept stage through to Series A. The firm expects to invest about $4 million across the life of an investment, with early investments structured as tranches that reflect technological milestones. The firm focuses on companies in the US and Canada, but is open to opportunities globally provided the company is focused on the USA as a primary market.

The firm focuses on building platforms of technology IP. In medical technology, the firm focuses on several specific technology verticals: healthcare robotics (particularly surgical robots), microfluidics (for both diagnostic and biotech R&D purposes), nanotechnology, healthcare 3D printing (including prosthetics, implants and tissue), data science, and the “omic” fields (genomics, proteomics and microbiomics). Technologies that fall between these core areas are also of interest, including biosensors and point of care diagnostics. The firm is open to investing in any disease area, and does not invest in drugs. The firm will only invest in companies developing technologies that have the potential to become a platform that produces a range of products. Repurposed/repositioned technologies are not of interest. Software opportunities will only be considered if the software is patentable.

The firm prefers to invest in very early-stage opportunities, including those that are pre-prototype and pre-patent filing, but may also consider companies that have fully developed their technology. The firm is a highly IP-focused investor and is therefore interested in technological opportunities that can provide both depth and breadth in terms of product potential, particularly those that can develop future applications in industries beyond the life science field.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm and investment bank based in Las Vegas, Nevada, makes investments from its own capital and typically has a two-pronged approach in making investments while also providing guidance in the structure and development of the company. The firm looks at a broad range of sectors, including life science and healthcare with a particular interest in consumer products for direct investing. The firm typically leads investments and invests $100K to a couple million per company. The firm invests on a global level, and seeks companies based all over the world.

The firm is indication agnostic and open to opportunities in healthcare IT, diagnostics, medical devices of all classes, and laboratory equipment and drug development enabling technology. The firm is particularly interested in technology involving software, though is not as open to biotech therapeutics because of the longer time line to commercialization. The firm is typically interested in later stage companies that are generating revenue, though would be open to looking at opportunities at all stages.

The firm will typically provide guidance and leadership support after an investment, and would support the company with future endeavors, including joint ventures and licensing partnerships. The firm would take a board seat after an investment, and would help fill the management team if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A firm based in Northern California makes seed and venture round investments in the form of equity or convertible loans. Investments may range up to $500,000, with the potential for follow-on investments. The firm prefers to support companies based in Northern California or with ties to the region, and plans to make approximately 2 further investments.

The firm is seeking to invest in products that can be used by hospitals or health systems to solve major problems. The firm invests in medical technology, healthcare IT and also has some interest in diagnostics. In the medical device sector, the firm invests in projects at both preclinical and clinical stages of development. The firm has diverse interests and will consider investing in any area of the medical device and healthcare IT/connected device field, but possesses specialist expertise in radiology, molecular imaging/imaging devices, and electro mechanical medical devices. In addition to these areas of expertise, the fund is interested in subsectors in which the Davis/Sacramento region provides significant expertise such as regenerative medicine and telehealth. In general, the firm is interested in technologies that improve standards of care or deliver more time- or cost-efficiency for healthcare providers.

The firm works with health systems in Northern California to launch pilot projects in order to vet new technologies from the fund’s portfolio. The firm therefore focuses on opportunities that can be de-risked with this method. The firm prefers to exit investments in a short timeframe (about 2 years), and seeks a board seat in portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A large US-based foundation is dedicated to finding cures for blood cancer patients and invests up to $20 million of its funds per year in assets that that have the potential to change the standard of care for patients with blood cancer. The foundation invests on average $3-4 million dollars per company in a cost sharing basis, but has made investments ranging from $1.2 million-$12 million. The firm looks to provide tranched equity funding or sponsored research upon milestones for an ROI based on a mutually agreed upon definitive arrangement. The firm makes investments in innovative assets in Proof-of-Concept in patient stage of development and is looking to make 3-5 investments per year. The foundation invests globally, and will invest alone or as part of a syndicate with other investors.

The foundation is looking to invest in companies developing either a therapeutic, device or a diagnostic or supportive care product that will benefit patients with blood cancer with urgent unmet medical needs and will consider any sub sector. The foundation’s target stage however is in companies that are just beginning to obtain proof of concept data in patients; however the firm has invested in companies that have products in stages of development including IND-enabling, phase I, phase II and phase III of clinical trials.

The foundation will consider investment in a private or public company that has capital resources of their own. The foundation looks for companies with a management team that has industry experience taking drugs through the development and the regulatory process, ability to execute on a plan and strong scientific and business leadership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com